Asieris Pharmaceuticals (Stock Code: 688176.SH), a trailblazer in the global biopharmaceutical industry with a focus on genitourinary tumors and related diseases, has today unveiled the promising results of a landmark multicenter Phase III global clinical study for its innovative non-surgical treatment for cervical High-Grade Squamous Intraepithelial Lesion (HSIL). This breakthrough marks a significant advancement in the fight against cervical precancerous conditions, offering a new beacon of hope for women worldwide.

APL-1702, a pioneering cold light photodynamic drug-device combination product, has been validated as the world's first non-surgical treatment for cervical HSIL with proven efficacy. The global study has showcased an 89.4% increase in the response rate compared to the placebo group, alongside a commendable safety profile and a notable advancement in the clearance of high-risk HPV16 and/or HPV18.

This groundbreaking study, spearheaded by Dr. Jinghe Lang of Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences, signifies a major leap forward in cervical HSIL treatment. Conducted across multiple countries, including China, Germany, and the Netherlands, the study's results were presented at prestigious forums such as the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN) Congress and the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting.

With cervical cancer ranking as the fourth most common cancer among women globally, the need for effective non-surgical treatments has never been more urgent. Current surgical options, while effective, come with risks of complications that can affect a woman's reproductive health and long-term wellbeing. APL-1702's introduction is poised to revolutionize treatment approaches, offering a less invasive, fertility-preserving alternative.

The response from the medical community has been overwhelmingly positive. Professor Chen Fei of Peking Union Medical College Hospital hailed the study's success as a monumental achievement in HSIL treatment, emphasizing the significant benefit of preserving the intact cervix. Professor Qiao Youlin, a WHO Global Expert on Cervical Cancer Elimination, highlighted the public health value of APL-1702 in the broader context of cervical cancer prevention and control.

Asieris Pharmaceuticals is gearing up for the submission of a new drug application in China in Q2 2024 and is making strides in product development outside of China. Dr. Linda Wu, Chief Development Officer at Asieris, expressed gratitude to everyone involved in the study and optimism for the rapid progression towards making APL-1702 available to patients globally.

This innovative treatment stands not only as a medical breakthrough but also as a symbol of hope for millions of women at risk of cervical cancer, marking a pivotal moment in the ongoing battle against this devastating disease.